Update
$bluebird bio(BLUE.US$ Bluebird Bio Provides Update; Sees Prelim. Unaudited Cash And Cash Equivalents ~$275M
Benzinga· 3 mins ago
Significant momentum behind LYFGENIA launch with 35 Qualified Treatment Centers accepting patient referrals and payer agreements in place covering approximately 200 million U.S. lives
Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start for LYFGENIA expected in Q1 2024
Cash, cash equivalents and marketable securities expected to fund current operations into Q1 2025
Highlights from the Company's update include:
Synergies with ZYNTEGLO commercial network are accelerating LYFGENIA commercial launch in 2024![]()
Benzinga· 3 mins ago
Significant momentum behind LYFGENIA launch with 35 Qualified Treatment Centers accepting patient referrals and payer agreements in place covering approximately 200 million U.S. lives
Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start for LYFGENIA expected in Q1 2024
Cash, cash equivalents and marketable securities expected to fund current operations into Q1 2025
Highlights from the Company's update include:
Synergies with ZYNTEGLO commercial network are accelerating LYFGENIA commercial launch in 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
71129854 : They need to sell the company…that’s it
TrytosaveabitOP 71129854: Hehehe! They need a buyer for the right price and I’m sure they would consider it? Hehehe GL